Physician profile
Gary Webb
NPI 1063962140
$5,767.21
in general payments reported to CMS, 2019-2025
23 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $625 · 2022: $1,025 · 2023: $1,242 · 2024: $1,297 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,089 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,089.39 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $921.37 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $626.29 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $529.60 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $503.98 | 2022-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $496.60 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $476.53 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $379.15 | 2021-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $267.89 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $243.48 | 2022-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $197.50 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $192.62 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $182.72 | 2021-2024 | Fanapt, Hetlioz |
| Corium, LLC | $145.86 | 2022-2025 | Azstarys |
| Biogen, INC. | $112.03 | 2024-2025 | Zurzuvae |
| Tris Pharma INC | $106.88 | 2022-2025 | Dyanavel Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $99.51 | 2022-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $84.03 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $64.44 | 2021-2022 | |
| Indivior INC. | $49.34 | 2022-2025 | Sublocade |
| Bausch Health US, LLC | $23.49 | 2023 | Aplenzin |
| Merck Sharp & Dohme LLC | $23.40 | 2022 | |
| Ironshore Pharmaceuticals INC. | $23.13 | 2024 | |
| Almatica Pharma LLC | $17.37 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.